Loading
A public investment fund would match private money in the riskiest early trials of truly new cancer drugs, taking a small share of future royalties so that taxpayers gain when the bets pay off.
A sovereign or supranational fund co-invests one-to-one alongside private investors in phase 1 trials of assets that meet a first-in-class test (a target or mechanism with no approved analogue), in exchange for a royalty stake or equity. The fund's return is portfolio-level and long-term; its purpose is to lower the private cost of capital for novel mechanisms relative to me-too assets. The Cancer Prevention and Research Institute of Texas (CPRIT) and the California Institute for Regenerative Medicine (CIRM) show public bodies can invest in translational biotech with revenue-sharing and attract companies; the EU's Innovative Health Initiative and BARDA venture arms are related models.
Shares A diversified royalty pool that finances academic phase 1 trials across fifty assets, A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares Government reinsurance for phase 2 failures of first-in-class cancer drugs, Incentives reward me-too drugs and marginal gains.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares A diversified royalty pool that finances academic phase 1 trials across fifty assets, The valley of death between lab and product.
Shares Government reinsurance for phase 2 failures of first-in-class cancer drugs, Incentives reward me-too drugs and marginal gains.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.